Tempus AI Surges Amid Merck and Moderna's Cancer Vaccine Trial Update
Tempus AI (TEM) experienced a significant weekly gain of 39.5% despite broader market declines in the S&P 500 (-1.9%) and Nasdaq Composite (-2.8%). The surge was driven by positive Phase 3 trial results from Merck and Moderna for an mRNA cancer vaccine combined with Keytruda, which showed improved outcomes compared to using Keytruda alone. The news boosted investor confidence in Tempus AI due to its pending acquisition of Personalis, the company behind genomic tumor-profiling technology used in developing the vaccines. The binding agreement is expected to close late this year or early 2027 and could provide strong tailwinds for Tempus as personalized vaccine development gains momentum. While Tempus's stock has surged recently, it remains down about 10% over the past year. Nonetheless, the trial results are seen as a validation of Personalis’s NeXT Platform and bode well for Tempus's long-term growth in precision medicine and genomic diagnostics.
Topics: acquisition AI biotech healthcare mRNA vaccines